All the news

The European Commission this week granted marketing authorisation for tenofovir alafenamide, to be sold under the brand name Vemlidy, for the treatment of chronic hepatitis B virus (HBV) infection, according ...

An experimental immune-based therapy for chronic hepatitis B combined with tenofovir was safe and well tolerated but did not lead to greater reductions in hepatitis B surface antigen (HBsAg) than the antiviral alone, ...

The nucleic acid polymers REP 2139 and REP 2165 led to hepatitis B surface antigen (HBsAg) reduction or clearance when combined with tenofovir and pegylated interferon, according to early results from a small ...

Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus (HBV) but causes less bone mineral loss, according to a report this ...

Several cheap interventions can significantly boost engagement with the continuum of care for viral hepatitis, a systematic literature review and a series of meta-analyses published in The Lancet Infectious Diseases show. Programmes led by ...

Hepatitis B virus (HBV) could be eliminated as a global health threat with a scale-up of vaccination coverage, enhanced efforts to prevent vertical (mother-to-child) transmission and expansion of testing and treatment, according to ...